Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Vertex Pharmaceuticals CEO & President Reshma Kewalramani reported open-market sales of 40,000 shares of Vertex common stock on February 27, 2026 under a pre-arranged Rule 10b5-1 trading plan entered into on November 17, 2025. The shares were sold at prices ranging from $479.75 to $496.95, and she held 98,278 shares directly after the final transaction.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold common stock in a planned transaction. On February 27, 2026, she completed an open-market sale of 2,329 shares of Vertex common stock at an average price of $480.31 per share. After the sale, she directly owned 37,734 shares. The trade was made under a pre-established Rule 10b5-1 trading plan entered on November 20, 2025.
Joy Liu reported proposed sales of company common stock under Form 144. The notice lists multiple sales and recent transactions: 552 shares on 12/29/2025, 1,385 shares on 01/05/2026, 812 shares on 02/12/2026, and 9,320 shares on 02/13/2026. The filing also shows a grant/vesting of 892 restricted shares on 02/10/2025.
Vertex Pharmaceuticals senior vice president and chief accounting officer Kristen Ambrose reported an open-market sale of 357 shares of common stock at $483.36 per share. After this transaction, she directly holds 6,624 shares. The sale was made under a pre-established, company-approved Rule 10b5-1 trading plan.
VRTX submitted a Form 144 notice reporting the proposed sale of 40,000 common shares. The filing lists an aggregate dollar amount of $19,738,905.28 and shows 254,034,190 shares on the line that includes 02/27/2026.
The entries list multiple restricted stock vesting dates (02/10/2025, 02/17/2025, 02/24/2025, 02/26/2025) with vesting quantities of 9,681, 6,998, 8,282, and 15,039 shares respectively. The form identifies Fidelity Brokerage Services LLC as the broker on a NASDAQ-listed common security.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., the company’s EVP, COO and CFO, reported a Form 4 transaction involving company common stock. On February 24, 2026, he had 1,744 shares of Vertex common stock disposed of in a transaction coded “F,” which represents payment of tax liability by delivering securities, at a price of $485.11 per share. After this tax-withholding disposition, Wagner directly owned 47,042 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported two transactions in Vertex common stock. She completed an open-market sale of 260 shares at $486.35 per share under a company-approved Rule 10b5-1 trading plan. In a separate transaction, she disposed of 1,627 shares at $485.11 per share to cover tax obligations. After these transactions, she directly holds 46,763 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported share sales and related tax withholding transactions. On February 25, 2026, he completed an open-market sale of 1,846 shares of common stock at $486.35 per share, leaving him with 55,570 directly held shares.
On February 24, 2026, he disposed of 1,518 shares of common stock at $485.11 per share to cover tax obligations by delivering shares. He also reported indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in a trust. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 18, 2025.
Vertex Pharmaceuticals executive Duncan McKechnie reported multiple stock transactions. On February 25, 2026, he made open-market sales of 2,500 common shares at $486.35 per share and 2,410 shares at $489.00 per share.
On February 24, 2026, 873 shares were disposed of at $485.11 per share to cover tax obligations by delivering shares. After these transactions, he directly owned 17,559 Vertex common shares. The filing notes the sales were made under a company-approved Rule 10b5-1 trading plan entered on November 25, 2025.